Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Vir Biotechnology Inc Market Cap
The Vir Biotechnology Inc (VIR) share price is expected to increase by 270.6% over the next year. This is based on calculating the average 12-month share price estimate provided by 9 stock analysts who have covered VIR. Price targets range from $10 at the low end to $110 at the high end. The current analyst consensus for VIR is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
Vir Biotechnology Inc has a total of 9 Wall St Analyst ratings. There are 6 buy ratings, 3 ratings, and 0 sell ratings. Since most analysts have a buy consensus rating, the expectation is that Vir Biotechnology Inc will outperform the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.
These are the latest 20 analyst ratings of VIR.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Patrick Trucchio HC Wainwright & Co. | Buy | $110 | Reiterates | Nov 20, 2024 |
| Joseph Stringer Needham | Buy | $19 | Reiterates | Nov 20, 2024 |
| Patrick Trucchio HC Wainwright & Co. | Buy | $110 | Reiterates | Nov 4, 2024 |
| Gena Wang Barclays | Overweight | $26 | Maintains | Nov 4, 2024 |
| Joseph Stringer Needham | Buy | $19 | Reiterates | Nov 1, 2024 |
| Patrick Trucchio HC Wainwright & Co. | Buy | $110 | Reiterates | Aug 20, 2024 |
| Gena Wang Barclays | Overweight | $28 | Maintains | Aug 2, 2024 |
| Michelle Gilson Morgan Stanley | Equal-Weight | $15 | Maintains | Jun 6, 2024 |
| Patrick Trucchio HC Wainwright & Co. | Buy | $110 | Reiterates | Jun 5, 2024 |
| Joseph Stringer Needham | Buy | $19 | Maintains | Jun 5, 2024 |
| Patrick Trucchio HC Wainwright & Co. | Buy | $110 | Reiterates | May 24, 2024 |
| Patrick Trucchio HC Wainwright & Co. | Buy | $110 | Reiterates | May 7, 2024 |
| Eric Joseph JP Morgan | Neutral | $12 | Maintains | May 3, 2024 |
| Joseph Stringer Needham | Buy | $15 | Reiterates | May 3, 2024 |
| Patrick Trucchio HC Wainwright & Co. | Buy | $110 | Reiterates | Mar 15, 2024 |
| Eric Joseph JP Morgan | Neutral | $10 | Maintains | Feb 23, 2024 |
| Patrick Trucchio HC Wainwright & Co. | Buy | $110 | Maintains | Feb 14, 2024 |
| Eric Joseph JP Morgan | Neutral | $9 | Downgrade | Jan 29, 2024 |
| Patrick Trucchio HC Wainwright & Co. | Buy | $85 | Maintains | Jan 23, 2024 |
| Joseph Stringer Needham | Buy | $15 | Maintains | Nov 3, 2023 |
When did it IPO
2019
Staff Count
587
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Dr. Marianne De Backer M.B.A., M.Sc., Ph.D.
Market Cap
$1.10B
In 2023, VIR generated $39.5M in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that VIR's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Tue, 26 Nov 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - Vir Biotechnology will host a virtual investor event on January 8, 2025, to discuss initial data from its Phase 1 trials for VIR-5818 and VIR-5500, and updates on the PRO-XTENâ„¢ platform.
Why It Matters - Vir Biotechnology's upcoming investor event will reveal initial data on promising cancer treatments, which could significantly impact stock performance and investor sentiment in the biotech sector.
Mon, 25 Nov 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - Vir Biotechnology's CEO, Marianne De Backer, will speak at the Evercore ISI HealthCONx Conference on December 3 at 6:10 a.m. PT. A live webcast will be available on their website.
Why It Matters - Marianne De Backer's participation in a major healthcare conference could signal strategic updates or insights into Vir Biotechnology's direction, influencing investor sentiment and stock performance.
Mon, 18 Nov 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - Vir Biotechnology received a positive opinion from the EMA for orphan drug designation of tobevibart and elebsiran for chronic hepatitis delta, supported by promising Phase 2 trial data.
Why It Matters - Positive orphan drug designation for tobevibart and elebsiran boosts Vir Biotechnology’s prospects in treating chronic hepatitis delta, potentially enhancing market value and investor confidence.
Mon, 18 Nov 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - Vir Biotechnology announced positive results from its SOLSTICE Phase 2 trial for tobevibart, achieving 100% virologic response in chronic hepatitis delta patients.
Why It Matters - Positive trial results for Vir Biotechnology's treatment for chronic hepatitis delta indicate strong potential for market approval, likely boosting stock value and investor confidence.
Fri, 15 Nov 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - Vir Biotechnology announced promising end-of-treatment data from its Phase 2 MARCH study, showing notable HBsAg loss in chronic hepatitis B patients using tobevibart and elebsiran.
Why It Matters - Positive clinical trial results for Vir Biotechnology could lead to increased investor confidence, potential market growth, and elevated stock prices due to advancements in hepatitis B treatment.
Tue, 05 Nov 2024
Sentiment - POSITIVE
Source - Seeking Alpha
Summary - Vir's main value drivers are its HDV and HBV treatments, with key catalysts in Q4 2024 and 2025. The company is pivoting to oncology, cutting 25% of its workforce to save $50M annually.
Why It Matters - VIR's focus on hepatitis treatments and strategic shift to oncology, paired with cost-cutting measures, may enhance profitability and growth potential, impacting stock performance.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
